# Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

> **NCT03332771** · PHASE3 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 954 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sotagliflozin (SAR439954)
- **DRUG:** Glimepiride
- **DRUG:** Metformin
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03332771
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2019-08-06
- **Final completion:** 2019-09-06
- **Target enrollment:** 954 (ACTUAL)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332771, "Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03332771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*